Source
Author: unknown
Eli Lilly to buy genetic medicine developer Akouos for $487 million [Deals Market Headlines | Breaking Stock Market News | Reuters]
Related Posts
Novo Nordisk and Septerna Forge $2.2 Billion Alliance to Accelerate Next-Generation Obesity Therapeutics
Click here for seasoned global CorpDev/ M&A/ PE expertise on demand In a strategic move to consolidate its leadership in the rapidly expanding obesity drug market, Novo Nordisk announced a landmark...
GSK’s $2 Billion Strategic Bet on Liver Disease Innovation: Reshaping the Hepatology Landscape
Click here for seasoned global CorpDev/ M&A/ PE expertise on demand In a bold move to secure leadership in the rapidly evolving hepatology sector, GSK announced a $2 billion acquisition of Boston...
Bain Capital Nears $10B Pharma Services Play Amid GLP-1 Market Surge
Click here for seasoned global CorpDev/ M&A/ PE expertise on demand Deal at a Glance ⚖️ Valuation: $10B+ enterprise value 📈 Key Growth Driver: 78% CAGR in GLP-1 drug packaging since 2022 🩺...
HistoSonics’ $2.5 Billion Strategic Crossroads: A Pivotal Moment for Non-Invasive Oncology Innovation
HistoSonics, the Johnson & Johnson-backed pioneer of histotripsy technology, stands at the center of a high-stakes acquisition battle that could redefine tumor treatment paradigms. With Medtronic,...